Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

ProMIS Neurosciences Inc. - Common Shares (NQ: PMN )

0.7690 -0.0220 (-2.78%)
Streaming Delayed Price Updated: 3:32 PM EDT, Mar 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about ProMIS Neurosciences Inc. - Common Shares

< Previous 1 2 Next >
ProMIS Neurosciences Showcases Preclinical Data on Platform Derived Vaccines for Neurodegenerative Diseases at the American Academy of Neurology 2025 Annual Meeting
From ProMIS Neurosciences Inc.
Via GlobeNewswire
ProMIS Neurosciences to Participate in the 37th Annual Roth Conference
From ProMIS Neurosciences Inc.
Via GlobeNewswire
ProMIS Neurosciences Doses First Patients in Phase 1b PRECISE-AD Trial of PMN310 for Alzheimer’s Disease
From ProMIS Neurosciences Inc.
Via GlobeNewswire
ProMIS Neurosciences to Participate in Guggenheim Securities SMID Cap Biotech Conference
From ProMIS Neurosciences Inc.
Via GlobeNewswire
ProMIS Neurosciences Issues Letter to Shareholders
From ProMIS Neurosciences Inc.
Via GlobeNewswire
ProMIS Neurosciences Initiates Phase 1b Clinical Trial (PRECISE-AD) in Alzheimer’s Disease
Targeting toxic oligomers without binding to plaque, designed to reduce the risk of ARIA and potentially deliver enhanced outcomes for patients 
From ProMIS Neurosciences Inc.
Via GlobeNewswire
ProMIS Neurosciences to Participate in 7th Annual Evercore HealthCONx Conference
From ProMIS Neurosciences Inc.
Via GlobeNewswire
ProMIS Neurosciences Announces Third Quarter 2024 Financial Results and Recent Highlights
From ProMIS Neurosciences Inc.
Via GlobeNewswire
ProMIS Neurosciences to Participate in Guggenheim’s Inaugural Healthcare Innovation Conference
From ProMIS Neurosciences Inc.
Via GlobeNewswire
ProMIS Neurosciences Presents Positive Data from PMN310 Phase1a Clinical Trial at the 17th Clinical Trials on Alzheimer’s Disease Conference
From ProMIS Neurosciences Inc.
Via GlobeNewswire
ProMIS Neurosciences to Showcase PMN310’s Ability to Target Toxic Oligomers and Distinguish from Other Amyloid-Beta Oligomers in Preclinical Studies at the 4th International Conference on Cognitive & Behavioral Neurosciences
From ProMIS Neurosciences Inc.
Via GlobeNewswire
ProMIS Neurosciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference
From ProMIS Neurosciences Inc.
Via GlobeNewswire
ProMIS Neurosciences Announces Second Quarter 2024 Financial Results and Recent Highlights
From ProMIS Neurosciences Inc.
Via GlobeNewswire
ProMIS Neurosciences Announces Data on the Pathogenic Role of Toxic Misfolded SOD1 Aggregates in ALS Published in Acta Neuropathologica and Open Biology
From ProMIS Neurosciences Inc.
Via GlobeNewswire
ProMIS Neurosciences to Participate in BTIG Virtual Biotechnology Conference 2024
From ProMIS Neurosciences Inc.
Via GlobeNewswire
ProMIS Neurosciences Showcases Novel Vaccine Approach for Maximal Targeting of Toxic Amyloid-Beta Oligomers at the 2024 Alzheimer’s Association International Conference
From ProMIS Neurosciences Inc.
Via GlobeNewswire
ProMIS Neurosciences Reports Positive Top-Line Data from its Phase 1a Alzheimer's Trial
From ProMIS Neurosciences Inc.
Via GlobeNewswire
ProMIS Neurosciences Announces Up to $122.7 Million Private Placement Financing
From ProMIS Neurosciences Inc.
Via GlobeNewswire
ProMIS Neurosciences Announces First Quarter 2024 Financial Results and Recent Highlights
Top-line data from first-in-human Phase 1a clinical trial of PMN310 as a treatment for Alzheimer’s disease on track for mid-2024 
From ProMIS Neurosciences Inc.
Via GlobeNewswire
ProMIS Neurosciences Publishes Study Highlighting Oligomer Selectivity and Benefit of Amyloid-Beta-Directed Antibodies
Study results support differentiation of PMN310 from other amyloid-beta-directed antibodies 
From ProMIS Neurosciences Inc.
Via GlobeNewswire
ProMIS Neurosciences Publishes in the Journal of Biological Chemistry on the Interaction Between Pathogenic Proteins as a Treatment Target for ALS
Study results support ProMIS’ TDP-43 misfolding-specific epitope as a potential therapeutic target for Amyotrophic Lateral Sclerosis (ALS) 
From ProMIS Neurosciences Inc.
Via GlobeNewswire
ProMIS Neurosciences to Present in Upcoming Investor Conferences in April
From ProMIS Neurosciences Inc.
Via GlobeNewswire
ProMIS Neurosciences Announces Full Year 2023 Financial Results and Recent Highlights
Top-line data from first-in-human Phase 1a clinical trial of PMN310 as a treatment for Alzheimer’s disease on track for mid-2024 
From ProMIS Neurosciences Inc.
Via GlobeNewswire
ProMIS Neurosciences Strengthens Global Intellectual Property Portfolio
Adds Key U.S. and International Patent Allowances to Further Protect the Company’s Monoclonal Antibody Therapeutic for the Treatment of Alzheimer’s Disease 
From ProMIS Neurosciences Inc.
Via GlobeNewswire
ProMIS Neurosciences to Present at the 2024 BIO CEO & Investor Conference
From ProMIS Neurosciences Inc.
Via GlobeNewswire
ProMIS Neurosciences Achieves Milestone in Development of Therapeutic Alpha-Synuclein Vaccine
Lead vaccine candidate selected for advancement against synucleinopathies including Multiple System Atrophy, Parkinson’s disease and Dementia with Lewy bodies 
From ProMIS Neurosciences Inc.
Via GlobeNewswire
ProMIS Neurosciences Issues Letter to Shareholders
From ProMIS Neurosciences Inc.
Via GlobeNewswire
ProMIS Neurosciences, Inc. Announces Leadership Transition
Appoints Neil Warma, Industry Leader and ProMIS Board Member, as Interim Chief Executive Officer 
From ProMIS Neurosciences Inc.
Via GlobeNewswire
ProMIS Neurosciences Announces Publication on Novel Target for ALS
From ProMIS Neurosciences Inc.
Via GlobeNewswire
ProMIS Neurosciences Doses First Subjects in Phase 1a Clinical Trial of PMN310 to Treat Alzheimer’s Disease
Advances novel monoclonal antibody designed to be highly selective for toxic oligomers of amyloid-beta (Aβ) in first-in-human study 
From ProMIS Neurosciences Inc.
Via GlobeNewswire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.